Johnson & Johnson announced new long-term follow-up data from the Phase 1b/2 CARTITUDE-1 study, highlighting significant advancements in the treatment of relapsed or refractory multiple myeloma (RRMM). The study revealed that 33 percent of patients treated with CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) achieved progression-free survival $(PFS)$ of five years or more with just a single infusion, without the need for maintenance or additional anti-myeloma therapy. These findings underscore the potential of CARVYKTI® to deliver lasting treatment-free remissions, even in heavily pre-treated populations. Notably, in a subset of 12 patients evaluated at a single site, all remained minimal residual disease $(MRD.AU)$ negative and imaging negative throughout the five-year follow-up period. These results were presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in The Journal of Clinical Oncology, showcasing the compelling overall survival and progression-free benefits observed in the study.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.